SCHEMBL2532650

SCHEMBL2532650

CC(C)(C)c1ccc(Oc2ccc(-c3ccc(OC(F)(F)F)cc3)cc2/C=C\C(=O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.44
IP6K3 Q96PC2 1/20 0.44
IP6K2 Q9UHH9 1/20 0.44
GAA P10253 1/20 0.44
SERPINE1 P05121 1/20 0.43
TRPV1 Q8NER1 2/20 0.43
HTT P42858 1/20 0.42
ESR1 P03372 2/20 0.42
NR1H4 Q96RI1 2/20 0.41
EPHX2 P34913 1/20 0.41
RXRA P19793 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
KMT2A Q03164 1/20 0.39
AURKA O14965 1/20 0.39
TPX2 Q9ULW0 1/20 0.39
PPARD Q03181 1/20 0.39
DHODH Q02127 1/20 0.39
SLC6A2 P23975 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2532652 1.00 IP6K1 (0.44) IP6K1IP6K3IP6K2GAASERPINE1
SCHEMBL13581141 0.94 IP6K1 (0.44) IP6K1IP6K3IP6K2GAASERPINE1
SCHEMBL2536942 0.92 IP6K1 (0.49) IP6K1IP6K3IP6K2GAAHTT
SCHEMBL2536938 0.92 IP6K1 (0.49) IP6K1IP6K3IP6K2GAAHTT
SCHEMBL15434108 0.91 IP6K1 (0.46) IP6K1IP6K3IP6K2GAASERPINE1
SCHEMBL15434135 0.91 IP6K1 (0.46) IP6K1IP6K3IP6K2GAASERPINE1
SCHEMBL15434144 0.91 IP6K1 (0.46) IP6K1IP6K3IP6K2GAASERPINE1
SCHEMBL15434124 0.91 GAA (0.45) IP6K1IP6K3IP6K2GAATRPV1
SCHEMBL2535476 0.89 TRPV1 (0.44) SERPINE1TRPV1NR1H4EPHX2PPARG
SCHEMBL2533890 0.87 PPARG (0.47) SERPINE1ESR1NR1H4EPHX2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 IP6K1 1399/4885IP6K3 2110/4885IP6K2 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.